Imperial College London
Portrait Picture

MsSarrahPeerbux

Faculty of Medicine, Department of Surgery & Cancer

Clinical Trial Manager
 
 
 
//

Contact

 

s.peerbux

 
 
//

Location

 

East WingCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Hajek:2019:10.1136/bmjopen-2018-026642,
author = {Hajek, P and Peerbux, S and Phillips-Waller, A and Smith, C and Pittaccio, K and Przulj, D},
doi = {10.1136/bmjopen-2018-026642},
journal = {BMJ Open},
pages = {e026642--e026642},
title = {Are ‘dual users’ who smoke and use e-cigarettes interested in using varenicline to stop smoking altogether, and can they benefit from it? A cohort study of UK vapers},
url = {http://dx.doi.org/10.1136/bmjopen-2018-026642},
volume = {9},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:sec><jats:title>Objectives</jats:title><jats:p>Smokers who use e-cigarettes (EC) do so mostly to stop smoking, but many continue to use both products. It is not known whether these ‘dual users’ are interested in stop-smoking medications and whether they can benefit from them.</jats:p></jats:sec><jats:sec><jats:title>Setting, participants and measures</jats:title><jats:p>Dual users were recruited over social media and posted study questionnaire and saliva kits at baseline, 3 and 6 months. Those interested in varenicline were posted the medication and received weekly calls over the first 6 weeks, followed by three calls at fortnightly intervals.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of 204 participants, 124 (61%, CI=54% to 68%) expressed interest in receiving varenicline and 80 (39%, CI=32% to 45%) started varenicline (varenicline users, VU). VU were more dependent smokers (F=6.2, p=0.01) with higher cigarette consumption (F=8.7, p<0.01) who were using stronger nicotine e-liquids (F=13.9, p<0.001) than dual users not opting for varenicline (varenicline non-users, VN). In terms of abstinence for at least 3 months at the 6-month follow-up, VU were more likely than VN to report abstinence from smoking (17.5% vs 4.8%, p=0.006, RR=3.6, CI:1.4 to 9.0), vaping (12.5% vs 1.6%, p=0.007, RR=7.8, CI:1.7 to 34.5) and both smoking and vaping (8.8% vs 0.8%, p=0.02, RR=10.9, CI:1.4 to 86.6). The differences were significant across sensitivity analyses (RRs=4.9 to 14.0; p=0.02 to p<0.001 at 3 months; RRs=3.0 to 14.0; p=0.01 to p<0.001 at 6 months). VU reported a greater reduction in enjoyment of vaping by the end of the varenicline use period (F=4.1, p=0.04) and recorded a significantly greater reduction in nicotine intake than VN at 3 months (F=13.9
AU  - Hajek,P
AU  - Peerbux,S
AU  - Phillips-Waller,A
AU  - Smith,C
AU  - Pittaccio,K
AU  - Przulj,D
DO  - 10.1136/bmjopen-2018-026642
EP  - 026642
PY  - 2019///
SN  - 2044-6055
SP  - 026642
TI  - Are ‘dual users’ who smoke and use e-cigarettes interested in using varenicline to stop smoking altogether, and can they benefit from it? A cohort study of UK vapers
T2  - BMJ Open
UR  - http://dx.doi.org/10.1136/bmjopen-2018-026642
VL  - 9
ER  -
Download